1. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non–small-cell lung cancer with PD-L1 tumor proportion score ≥ 50;Reck;J. Clin. Oncol.,2021
2. Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma : Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region;Shemesh,2021
3. Combinations take centre stage in PD1/PDL1 inhibitor clinical trials;Hodge;Nat. Rev. Drug Discov.,2021
4. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy : mechanism , combinations, and clinical outcome;Alsaab;Front. Pharmacol.,2017
5. Advances of PD-1/PD-L1 inhibitors in tumor immunotherapy;Yong-jun;J. Int. Transl. Med.,2017